pirfenidone has been researched along with nintedanib in 235 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 163 (69.36) | 24.3611 |
| 2020's | 72 (30.64) | 2.80 |
| Authors | Studies |
|---|---|
| Bailie, M; Campbell, PL; Dexheimer, T; Fox, DA; Haak, AJ; Hutchings, KM; Kahl, DJ; Khanna, D; Larsen, SD; Leipprandt, JR; Lisabeth, EM; Neubig, RR; Sun, D; Tsou, PS; Wen, B | 1 |
| Chen, L; Li, Y; Liu, K; Ma, T; Ma, X; Sun, H; Sun, X; Wang, C; Zheng, X; Zhu, Y | 1 |
| Günther, A; Korfei, M; Mahavadi, P; Markart, P; Ruppert, C; von der Beck, D | 1 |
| Lota, HK; Wells, AU | 1 |
| Ancochea, J; Bollo, E; Fernández-Fabrellas, E; Franquet, T; Molina-Molina, M; Montero, MA; Serrano-Mollar, A; Xaubet, A | 1 |
| Hunninghake, GM | 1 |
| Kingwell, K | 1 |
| Collard, HR; Ryerson, CJ | 1 |
| Ahluwalia, N; Shea, BS; Tager, AM | 1 |
| Kang, S | 1 |
| Covvey, JR; Mancl, EE | 1 |
| Cottin, V | 1 |
| Ratner, M | 1 |
| Drakopanagiotakis, F; Günther, A; Löh, B; Markart, P; von der Beck, D | 1 |
| Crooks, MG; Hart, SP | 1 |
| Goodwin, A; Jenkins, G | 1 |
| Abe, S; Azuma, A; Bando, M; Chida, K; Fujimoto, T; Hasegawa, Y; Inoue, Y; Klüglich, M; Kondoh, Y; Mochizuki, Y; Ogura, T; Okazaki, K; Sakamoto, W; Sugiyama, Y; Tadayasu, Y; Taniguchi, H | 1 |
| Cavazza, A; Crestani, B; Rossi, G; Spagnolo, P; Sverzellati, N; Tzouvelekis, A; Vancheri, C | 1 |
| Spagnolo, P | 1 |
| Collard, HR; Spagnolo, P; Wells, AU | 1 |
| Raghu, G; Selman, M | 1 |
| Kaminski, N; Rosas, IO | 1 |
| Corte, T; King, TE; Moodley, Y; Richeldi, L | 1 |
| Einecke, D | 1 |
| Chowdhury, BA; Karimi-Shah, BA | 1 |
| Bergmann, C; Distler, JH | 1 |
| Clegg, AJ; Colquitt, JL; Copley, VR; Loveman, E; O'Reilly, KM; Scott, DA | 1 |
| Morrow, T | 2 |
| Maher, TM; Richeldi, L; Spagnolo, P | 1 |
| Funke, M; Geiser, T | 1 |
| Crestani, B | 1 |
| Danoff, SK; Lancaster, LH; Meyer, KC; Nathan, SD | 1 |
| King, CS; Nathan, SD | 2 |
| Álvarez-Sala Walther, R; Gómez Carrera, L | 1 |
| Crestani, B; Porcher, R; Richeldi, L; Thabut, G | 1 |
| Behr, J; Kneidinger, N; Milger, K; Neurohr, C; Reichenberger, F | 1 |
| Kremer, MR; Wand, O | 1 |
| Bonella, F; Maher, TM; Spagnolo, P | 1 |
| Prasse, A | 1 |
| Elmufdi, F; Henke, CA; Kim, HJ; Perlman, DM; Tomic, R | 1 |
| George, G; Summer, R; Vaid, U | 1 |
| Belloli, EA; Flaherty, KR; Martinez, FJ | 1 |
| Furlow, B | 1 |
| Munakata, M | 1 |
| Locy, ML; Luckhardt, TR; Rangarajan, S; Thannickal, VJ | 1 |
| Bonella, F; Kreuter, M; Maher, TM; Spagnolo, P; Wijsenbeek, M | 1 |
| Morrow, TJ | 1 |
| Fraser, E; Hoyles, RK | 1 |
| Canestaro, WJ; Devine, BE; Forrester, SH; Ho, L; Raghu, G | 1 |
| Beyene, J; Brozek, J; Garcia, CC; Neupane, B; Raghu, G; Richeldi, L; Rochwerg, B; Schünemann, H; Zhang, Y | 1 |
| Kaarteenaho, R; Karvonen, H; Korpela, S; Lappi-Blanco, E; Lehtonen, ST; Sköld, MC; Sormunen, R; Veijola, A; Zagai, U | 1 |
| Wang, L; Zhang, FC; Zhang, X | 1 |
| Funke-Chambour, M; Geiser, T | 1 |
| Baba, T; Ikeda, S; Kitamura, H; Morita, M; Ogura, T; Sekine, A; Yamakawa, H | 1 |
| Beltramo, G; Borie, R; Crestani, B; Justet, A; Manali, ED; Pradère, P; Spagnolo, P | 1 |
| Hagmeyer, L; Priegnitz, C; Randerath, WJ; Treml, M | 1 |
| Corte, TJ; Jo, HE; Moodley, Y; Randhawa, S | 1 |
| Bacon, KB; Boehme, SA; DiTirro, DN; Franz-Bacon, K; Ly, TW | 1 |
| Bondue, B; Corhay, JL; Guiot, J; Henket, M; Louis, R | 1 |
| Jones, MG; Richeldi, L | 1 |
| Brown, KK | 1 |
| Calzetta, L; Cavalli, F; Cazzola, M; Matera, MG; Rogliani, P | 1 |
| Adegunsoye, A; Strek, ME | 1 |
| Roman, J; Santiago-Cornier, A; Vergne, Y; Vicary, GW; Young, LR | 1 |
| Fletcher, S; Jones, MG; Limbrey, R; Marshall, BG; Richeldi, L; Sgalla, G; Spinks, K | 1 |
| Robinson, HC | 1 |
| Clarke, DL; Crestani, B; Murray, LA; Sleeman, MA | 1 |
| Altraja, A; Bendstrup, E; Ferrara, G; Gudmundsson, G; Hilberg, O; Kaarteenaho, R; Myllärniemi, M; Sjåheim, T; Sköld, CM | 1 |
| Delanote, I; Verbeken, EK; Verleden, GM; Vos, R; Wuyts, WA; Yserbyt, J | 1 |
| Bayly, S; Brown, KK; Chien, JW; Collard, HR; Cottin, V; Gibson, KF; Gong, Q; Kaner, RJ; Lederer, DJ; Martinez, FJ; Moreau, E; Noble, PW; O'Riordan, TG; Patterson, SD; Raghu, G; Smith, V; Song, JW; Wells, AU; Whelan, TP; Wuyts, W; Zhang, JJ | 1 |
| Chang, S; Diamantopoulos, A; Esser, D; LeReun, C; Maher, TM; Rinciog, C; Watkins, M | 1 |
| Liou, JP; Liu, YM; Nepali, K | 1 |
| Antony, VB; Bae, S; de Andrade, J; Li, FJ; Li, H; Liu, G; Liu, RM; Luckhardt, T; Rangarajan, S; Surolia, R; Thannickal, VJ; Wang, Z; Zhou, Y | 1 |
| Aichler, M; Bächinger, HP; Behr, J; Eickelberg, O; Hatz, R; Heinzelmann, K; Ishikawa, Y; Knüppel, L; Staab-Weijnitz, CA; Walch, A | 1 |
| Aiello, M; Bertorelli, G; Bocchino, M; Chetta, A; Fiore-Donati, A; Fois, A; Marinari, S; Oggionni, T; Polla, B; Rosi, E; Sanduzzi, A; Stanziola, A; Varone, F | 1 |
| George, PM; Wells, AU | 2 |
| Collard, HR | 1 |
| Daigl, M; Edwards, SC; Fisher, M; Fleetwood, K; Glanville, J; Gsteiger, S; McCool, R | 1 |
| Dejonckheere, F; Maher, TM; Nathan, SD | 1 |
| Acosta, O; Ancochea, J; Bollo, E; Castillo, D; Fernández-Fabrellas, E; Molina-Molina, M; Rodríguez-Portal, JA; Valenzuela, C; Xaubet, A | 1 |
| Criner, GJ; Dass, C; Galli, JA; Pandya, A; Vega-Olivo, M; Zhao, H | 1 |
| Bi, Y; Chowdhury, BA; Karimi-Shah, BA; Paterniti, MO; Rekić, D; Wang, Y | 1 |
| Maher, TM; Spagnolo, P | 1 |
| Kitamura, H; Ogura, T | 1 |
| Bruni, T; Fabbrizzi, A; Gerardi, RE; Iovene, B; Lo Greco, E; Lombardi, F; Magnini, D; Montemurro, G; Richeldi, L; Tagliaboschi, L | 1 |
| Flaherty, KR; Martinez, FJ | 1 |
| Berardini, L; Leone, PM; Macagno, F; Mari, PV; Panico, L; Richeldi, L; Varone, F | 1 |
| Ashton, RW; Sathiyamoorthy, G; Sehgal, S | 1 |
| Leslie, K; Morell, F; Raghu, G; Vasakova, M; Walsh, S | 1 |
| Behr, J; Kreuter, M; Wälscher, J | 1 |
| Elia, D; Harari, S; Humbert, M | 1 |
| Bahudhanapati, H; Kass, DJ | 1 |
| AbuTarif, M; Bax, L; Chan, P; Chen, C; Huang, SP; Rosen, G; Soares, H; Zhang, N | 1 |
| Bautista, B; Felton, MK; Malesker, M; Morrow, LE | 1 |
| Raghu, G; Richeldi, L | 1 |
| Beatson, D; Chambers, DC; Chapman, S; Corte, TJ; de Boer, S; Glaspole, I; Goh, N; Grainge, C; Holland, A; Hopkins, P; Jo, HE; Jones, L; Keir, G; Moodley, Y; Reynolds, PN; Troy, LK; Whitford, H; Wilsher, M | 1 |
| Chaudhuri, N; Hayton, C | 1 |
| Grutters, JC; Kreuter, M; Quaresma, M; Richeldi, L; Ryerson, CJ; Stansen, W; Stowasser, S; Valeyre, D; Vancheri, C; Wiebe, S; Wuyts, WA | 1 |
| Axmann, J; Bonella, F; Jouneau, S; Maher, TM; Molina-Molina, M; Ripamonti, E; Russell, AM; Vancheri, C | 1 |
| Boccabella, C; Comes, A; Condoluci, C; Golfi, N; Inchingolo, R; Mastrobattista, A; Richeldi, L; Smargiassi, A | 1 |
| Bonella, F; Kolb, M; Wollin, L | 1 |
| Caminati, A; Cassandro, R; Harari, S; Torre, O | 1 |
| Raghu, G | 2 |
| Nathan, SD | 1 |
| Maher, TM | 1 |
| Tepede, A; Yogaratnam, D | 1 |
| Arízaga Maguregui, A; González Larrocha, O; Ortega Mera, U; Romero Rojano, P | 1 |
| Corwine, J; Danoff, S; Galiatsatos, P; Silhan, L | 1 |
| Behr, J; Bonella, F; Costabel, U; Geißler, K; Günther, A; Koschel, D; Kreuter, M; Müller-Quernheim, J; Prasse, A; Schönfeld, N; Sitter, H | 1 |
| Bénard, S; Catella, L; Cottin, V; Le Lay, K; Luciani, L; Porte, F | 1 |
| Criner, GJ; Vega-Olivo, M | 1 |
| Calvello, M; Iovene, B; Ori, M; Richeldi, L; Sgalla, G; Varone, F | 1 |
| Epstein Shochet, G; Shitrit, D; Wollin, L | 1 |
| Lewandowska, K | 1 |
| Boehm, PM; Gottlieb, J; Ius, F; Jaksch, P; Klepetko, W; Lambers, C; Lee, S; Ristl, R; Tudorache, I; Welte, T | 1 |
| Aryal, S; Nathan, SD | 1 |
| Lederer, DJ; Martinez, FJ | 1 |
| Asmani, M; Chen, Z; Hinz, B; Hsia, I; Li, Y; Velumani, S; Wawrzyniak, N; Zhao, R | 1 |
| Bengus, M; Fell, CD; Flaherty, KR; Gilberg, F; Huggins, JT; Nunes, H; Petzinger, U; Stauffer, JL; Sussman, R; Valenzuela, C; Wijsenbeek, M | 1 |
| Azuma, A; Bando, M; Date, H; Ebina, M; Fukuoka, J; Gemma, A; Goto, Y; Hasegawa, Y; Hattori, N; Homma, S; Inase, N; Inoue, Y; Ishii, Y; Izumi, S; Johkoh, T; Kido, T; Kishaba, T; Kishi, K; Miyamoto, A; Mukae, H; Nakayama, T; Nishioka, Y; Ogura, T; Sakamoto, S; Sasaki, S; Suda, T; Sugino, K; Taguchi, Y; Takahashi, H; Takahashi, K; Taniguchi, H; Watanabe, K; Yokoyama, A; Yoshino, I | 1 |
| Carrington, R; Jordan, S; Page, CP; Pitchford, SC | 1 |
| Burridge, K; Doerschuk, CM; Monaghan-Benson, E; Wittchen, ES | 1 |
| Kreuter, M; Quaresma, M; Richeldi, L; Stowasser, S; Vancheri, C; Wuyts, WA | 1 |
| Anand, A; Rajchgot, J; Stanbrook, MB | 1 |
| Calabrese, F; Lunardi, F; Pezzuto, F; Vuljan, SE | 1 |
| Achtar-Zadeh, N; Green, G; Jones, KD; Kukreja, J; Wolters, PJ; Xu, B; Zhang, Y | 1 |
| Azuma, A; Kashiwada, T | 1 |
| Alsafadi, HN; Behr, J; Buhl, L; Hermann, S; Hilgendorff, A; Klee, S; Königshoff, M; Lehmann, M; Lindner, M; Mutze, K; Ota, C; Wagner, DE | 1 |
| Kishaba, T | 2 |
| Ammar, R; Huang, X; Jarai, G; Li, L; Ravi, K; Thompson, J; Wang, Y; Zhang, Y | 1 |
| Bergna, M; de Andrade, J; Falk, J; Hallowell, R; Jouneau, S; Kondoh, Y; Morrow, L; Randerath, W; Richeldi, L; Strek, M; Tabaj, G; Varone, F | 1 |
| Albert, GR; Cantin, AM; Cesari, F; Gagnon, L; Hagerimana, A; Hernandez, P; Khalil, N; Kolb, M; Laurin, P; Manganas, H; Moran, JE; Parker, JM; Ryerson, CJ; Sawtell, R; Shapera, S; Turcotte, EE | 1 |
| Bondue, B; Castiaux, A; Doumont, G; Egrise, D; Goldman, S; Huaux, F; Lacroix, S; Mathey, C; Sherer, F; Van Simaeys, G | 1 |
| Blackwell, TS; Kropski, JA | 1 |
| Ballester, B; Cortijo, J; Milara, J | 1 |
| Heukels, P; Kool, M; Moor, CC; von der Thüsen, JH; Wijsenbeek, MS | 1 |
| Cottin, V; Fischer, A; Harari, S; Quaresma, M; Stowasser, S; Wollin, L | 1 |
| Hewitt, RJ; Maher, TM | 1 |
| Black, KE; Feneis, JF; Mark, EJ; Montesi, SB | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Katano, T; Kitamura, H; Oda, T; Ogura, T; Okuda, R; Sadoyama, S; Sekine, A; Shintani, R; Tabata, E; Takemura, T; Yamakawa, H | 1 |
| Bajwa, EK; El-Amine, M; Gorina, E; Gupta, R; Kaner, RJ; Lazarus, HM; Luckhardt, TR; Martinez, FJ; Mouded, M; Posada, K; Richeldi, L; Stauffer, J; Tutuncu, A | 1 |
| Baldi, F; Macagno, F; Panico, L; Pasciuto, G; Richeldi, L | 1 |
| Dempsey, TM; Limper, AH; Sangaralingham, LR; Sanghavi, D; Shah, ND; Yao, X | 1 |
| Liu, JP; Lv, XD; Pang, LJ | 1 |
| Cha, H; Cho, JM; Kim, HJ; Kim, HR; Kim, YS | 1 |
| Colquitt, JL; Loveman, E; O'Reilly, K; Scott, DA | 1 |
| Glassberg, MK | 1 |
| Distler, J; Fischer, A | 1 |
| Bast, A; Drent, M; Elfferich, MDP; Jessurun, NT; Proesmans, VLJ; Wijnen, PAHM | 1 |
| Chaudhuri, N; Kahn, N; Kreuter, M; Müller, V; Somogyi, V; Torrisi, SE | 1 |
| Bocchino, M; Boschetto, P; Casillo, V; Cerri, S; Ciervo, A; Flacco, ME; Luppi, F; Manno, M; Manzoli, L; Stendardo, M | 1 |
| Maher, TM; Strek, ME | 1 |
| Culver, DA; Glennie, J; Li, M; Olman, MA; Perelas, A; Scheraga, RG; van Kerkhove, K | 1 |
| Kolb, MR; Wongkarnjana, A; Yanagihara, T | 1 |
| Distler, O; Hoffmann-Vold, AM; Maher, TM; Volkmann, ER | 1 |
| Collins, BF; Raghu, G | 1 |
| Bacchi Reggiani, ML; Bandelli, G; Bassi, I; Betti, S; Carpano, M; Cerri, S; Clini, E; Donatelli, P; Garuti, M; Guerrieri, A; Luppi, F; Monari, M; Nava, S; Tonelli, R | 1 |
| Eichinger, M; Heussel, CP; Kahn, N; Kreuter, M; Lars, K; Palmucci, S; Polke, M; Sambataro, D; Sambataro, FM; Sambataro, G; Sarmand, N; Torrisi, SE; Vancheri, C; Wälscher, J | 1 |
| Chiba, H; Ikeda, K; Kuronuma, K; Mori, Y; Nishikiori, H; Otsuka, M; Takahashi, H; Umeda, Y; Yoshikawa, T | 1 |
| Flaherty, KR; Freiheit, EA; Holtze, CH; Kim, HJ; Limb, SL; Pan, WT; Raimundo, K; Stauffer, JL | 1 |
| Li, YH; Ye, Q | 1 |
| Calvello, M; Cerri, S; Donatelli, P; Iovene, B; Lo Greco, E; Luppi, F; Pavone, M; Richeldi, L; Sgalla, G; Vancheri, A; Vancheri, C; Varone, F | 1 |
| Cheng, YL; Li, LX; Shi, JX | 1 |
| Bocchino, M; Caminati, A; Faverio, P; Fumagalli, A; Gasbarra, M; Iovino, P; Petruzzi, A; Sanduzzi, A; Scalfi, L; Sebastiani, A; Stanziola, AA | 1 |
| Aerts, JGJV; Bresser, P; Chavannes, NH; Grutters, JC; Moor, CC; Mostard, RLM; Wijsenbeek, MS | 1 |
| Kreuter, M; Luppi, F; Moor, CC; Wuyts, WA | 1 |
| Barrett, VJ; Brockbank, S; Cruwys, S; Dabbagh, RQ; Genovese, F; Good, RB; Jessen, H; Karsdal, MA; Leeming, DJ; Nanthakumar, CB; Rønnow, SR; Sand, JMB; Sorensen, GL | 1 |
| Angibaud, A; Chauvin, P; Diridollou, T; Gaignon, T; Jouneau, S; Kerjouan, M; Lederlin, M; Lemerre, J; Rousseau, C; Salé, A; Sohier, L; Tas, M | 1 |
| Kahn, N; Kreuter, M; Torrisi, SE; Vancheri, C | 1 |
| Boulate, D; Crutu, A; Dauriat, G; Dolidon, S; Fabre, D; Fadel, E; Feuillet, S; Florea, V; Gazengel, P; Hanna, A; Le Pavec, J; Mercier, O; Mitilian, D; Mussot, S; Pradere, P | 1 |
| Franciosa, C; Richeldi, L; Sgalla, G; Simonetti, J | 1 |
| Adegunsoye, A; Alqalyoobi, S; Bowman, WS; Haczku, A; Lee, CT; Linderholm, A; Ma, SF; Noth, I; Oldham, JM; Pugashetti, JV; Sarma, N; Sperling, A; Strek, ME | 1 |
| Bonella, F; Maher, TM; Ryerson, CJ; Spagnolo, P; Tzouvelekis, A | 1 |
| Fellrath, JM | 1 |
| Condos, R; Deshwal, H; Gibson, CD; Kugler, MC; Munger, JS | 1 |
| Corral, M; DeYoung, K; Kong, AM | 1 |
| Kolb, MRJ; Scallan, C; Wongkarnjana, A | 1 |
| Hu, Z; Li, K; Lv, X | 1 |
| De Sadeleer, LJ; Van Raemdonck, D; Verleden, GM; Verleden, SE; Vos, R | 1 |
| Antoniou, K; Kamekis, A; Kokosi, M; Swigris, JJ; Symvoulakis, EK | 1 |
| Aerts, JGJV; Bresser, P; Dirksen, CD; Grutters, JC; Kimman, ML; Moor, CC; Mostard, RLM; Wijsenbeek, MS | 1 |
| Beloki, L; Carruthers, A; Chahboub, A; Clarke, D; Dunmore, R; Güler-Gane, G; Koch, S; Kuziora, M; Lewis, A; Liarte Marin, E; May, R; Miranda, E; Murray, L; Overed-Sayer, C; Parfrey, H; Rassl, D | 1 |
| Broder, MS; Chang, E; Corral, M; Gokhale, S; Reddy, SR | 1 |
| Bi, Y; Chen, J; Chowdhury, BA; Karimi-Shah, BA; Marathe, A; Paterniti, MO; Rekić, D; Wang, Y | 1 |
| Irfan, M; Trachalaki, A; Wells, AU | 1 |
| Di Martino, E; Polidori, P; Provenzani, A; Vitulo, P | 1 |
| Banerjee, S; Cui, H; Dey, T; Ge, J; Jiang, D; Liu, G; Liu, RM; Matthews, QL; Xie, N | 1 |
| Li, JW; Tan, K; Wang, GQ; Wu, Z; Yang, W; Zhang, C; Zhao, H | 1 |
| Dygai, A; Ermakova, N; Krupin, V; Kubatiev, A; Morozov, S; Nebolsin, V; Novikov, F; Pakhomova, A; Pan, E; Pershina, O; Sandrikina, L; Skurikhin, E; Widera, D; Zhukova, M | 1 |
| Li, SQ; Zou, H | 1 |
| Ahmad, K; Andrejak, C; Ba, I; Blanchard, E; Bondue, B; Bonniaud, P; Borie, R; Cottin, V; Crestani, B; Froidure, A; Funke-Chambour, M; Gamez, AS; Gondouin, A; Grutters, J; Hirschi, S; Jouneau, S; Justet, A; Kannengiesser, C; Klay, D; Manali, E; Marchand-Adam, S; Molina Molina, M; Naccache, JM; Nunes, H; Papiris, S; Porcher, R; Prévot, G; Reynaud-Gaubert, M; Tromeur, C; van Moorsel, C; Wemeau, L | 1 |
| Chen, TH; Chu, KA; Fu, YS; Hsu, CW; Kuo, FH; Lin, WR; Yeh, CC | 1 |
| Aimo, A; Bayes-Genis, A; Egea, OI; Emdin, M | 1 |
| Dempsey, TM; Limper, AH; Payne, S; Sangaralingham, L; Shah, ND; Yao, X | 1 |
| Drakopanagiotakis, F; Markart, P; Wygrecka, M | 1 |
| Guler, SA; Lindell, KO; Ryerson, CJ; Swigris, J | 1 |
| Ali, MF; Anderson, DK; Aubry, MC; Carmona, EM; Dasari, H; Egan, AM; Kottom, TJ; Limper, AH; Peikert, T; Shaughnessy, GF; Van Keulen, VP; Yi, ES | 1 |
| Auriemma, L; Costantini, A; De Vita, F; Di Fabio, C; Di Fabio, L; Esposito, F; Marinari, S; Petragnani, G; Santoleri, F; Spacone, A | 1 |
| Comes, A; Richeldi, L; Sgalla, G | 1 |
| Belhassen, M; Dalon, F; Nolin, M; Van Ganse, E | 1 |
| Bemiss, BC; Chung, PA; Reid, M; Warrior, K | 1 |
| Bando, M; Hara, H; Hashimoto, S; Hisata, S; Homma, S; Inase, N; Izumi, S; Kataoka, K; Kato, M; Mukae, H; Nishioka, Y; Ogura, T; Saito, Y; Sakamoto, S; Shimizu, Y; Tanino, Y; Waseda, Y; Watanabe, K; Yatera, K | 1 |
| Lerede, M; Richeldi, L; Sgalla, G | 1 |
| Asmani, M; Zhao, R | 1 |
| Bari, E; Corsico, AG; Ferrarotti, I; Perteghella, S; Richeldi, L; Saracino, L; Torre, ML | 1 |
| Lertjitbanjong, P; Moua, T; Petnak, T; Thongprayoon, C | 1 |
| Ando, M; Homma, S; Kishi, K; Ono, H; Sugino, K; Tsuboi, E; Watanabe, N | 1 |
| Aono, Y; Enomoto, N; Fujisawa, T; Furuhashi, K; Hasegawa, H; Hozumi, H; Inui, N; Karayama, M; Kono, M; Mori, K; Nakamura, H; Nakamura, Y; Naoi, H; Suda, T; Suzuki, Y; Yokomura, K | 1 |
| Dempsey, TM; Kelly, BT; Limper, AH; Moua, T; Payne, SR; Sangaralingham, LR; Shah, ND; Teague, TT; Thao, V | 1 |
| Bendstrup, E; Carlson, L; Durheim, MT; Hyldgaard, C; Kalafatis, D; Myllärniemi, M; Sjåheim, T; Sköld, CM; Sutinen, EM | 1 |
| Homma, S; Isshiki, T; Kishi, K; Miyoshi, S; Nakamura, Y; Sakamoto, S; Shimizu, H; Yamasaki, A | 1 |
| Kang, J; Song, JW | 1 |
| Kreuter, M; Marijic, P; Ruhnke, T; Schwarzkopf, L; Schwettmann, L; Trudzinski, F | 1 |
| Chambers, DC; Corte, TJ; Cox, IA; de Graaff, B; Glaspole, I; Moodley, Y; Palmer, AJ; Teoh, A; Walters, EH | 1 |
| Anevlavis, S; Archontogeorgis, K; Bonelis, K; Froudarakis, M; Ntolios, P; Paxinou, N; Steiropoulos, P; Voulgaris, A | 1 |
| Brunetti, ND; Casparrini, M; Correale, M; Foschino Barbaro, MP; Lacedonia, D; Scioscia, G; Simone, F; Stornelli, SR; Tricarico, L | 1 |
| Cordova, FC; Criner, GJ; Dorey-Stein, ZL; Galli, JA; Shapiro, W; Zhao, H | 1 |
| Comes, A; Lerede, M; Richeldi, L; Sgalla, G | 1 |
| Abdelaziz, A; Dutta, P; Finnerty, JP; Kamil, H; Ponnuswamy, A | 1 |
| Borah, BJ; Dempsey, TM; Limper, AH; Moriarty, JP; Thao, V | 1 |
| Hachisu, Y; Hisada, T; Koga, Y; Kouno, S; Maeno, T; Nakagawa, J; Saito, Y; Sawada, Y; Shin, Y; Sunaga, N; Takehara, K; Umetsu, K; Utsugi, M; Wakamatsu, I; Yatomi, M; Yoshimi, S | 1 |
| Borsino, C; Mazzoleni, L; Zovi, A | 1 |
| Ashish, S; Chanda, D; Chiles, J; Kumar, PL; McDonald, MN; Mobley, JA; Neptune, ER; Thannickal, VJ; Wilson, AC | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Katano, T; Kato, T; Kitamura, H; Oda, T; Ogura, T; Okuda, R; Sekine, A; Shintani, R; Tabata, E; Takemura, T; Yamakawa, H | 1 |
| Bouzillé, G; Fournier, D; Jouneau, S; Osmont, MN; Polard, E; Scailteux, LM | 1 |
| Behera, D; Deep, A; Gupta, S; Padhan, P; Priyadarshini, S; Singh, P | 1 |
| Belhassen, M; Bonniaud, P; Cottin, V; Dalon, F; Kirchgässler, KU; Nolin, M; Spagnolo, P; Van Ganse, E | 1 |
| Brown, KK; Costabel, U; Cottin, V; Danoff, SK; Fieuw, A; Ford, P; Groenveld, I; Helmer, E; Jenkins, RG; Jentsch, G; Kreuter, M; Maher, TM; Milner, J; Molenberghs, G; Penninckx, B; Prasad, N; Randall, MJ; Rocak, S; Seghers, I; Shao, L; Taneja, A; Van Den Blink, B; Vandenrijn, C; Verbruggen, N; Watkins, TR; Wijsenbeek, MS; Wuyts, WA | 1 |
| Aliberti, S; Amati, F; Blasi, F; Gramegna, A; Mantero, M; Polelli, V; Stainer, A | 1 |
94 review(s) available for pirfenidone and nintedanib
| Article | Year |
|---|---|
Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Enzyme Inhibitors; Epithelial Cells; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Alveoli; Pyridones | 2012 |
The evolving pharmacotherapy of pulmonary fibrosis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Interstitial Pneumonias; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Treatment Outcome | 2013 |
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Pyridones; Wound Healing | 2014 |
Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Anti-Inflammatory Agents; Azathioprine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Prednisone; Pyridones; Randomized Controlled Trials as Topic | 2014 |
[Antifibrotic treatment].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cystine; Drug Approval; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Vital Capacity | 2014 |
Novel approaches to pulmonary fibrosis.
Topics: Biomarkers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2014 |
Idiopathic pulmonary fibrosis: an update.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Health Services Needs and Demand; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Middle Aged; Pyridones; Risk Factors | 2015 |
Pharmacological treatment of idiopathic pulmonary fibrosis: an update.
Topics: Animals; Comorbidity; Disease Models, Animal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2015 |
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2015 |
Idiopathic pulmonary fibrosis: the turning point is now!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Disease Progression; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones | 2015 |
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions.
Topics: Age Factors; Aged; Antineoplastic Agents; Disease Management; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient-Centered Care; Precision Medicine; Prognosis; Pyridones | 2015 |
Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.
Topics: Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2015 |
[Novel therapies for idiopathic pulmonary fibrosis].
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Respiratory Mucosa; Survival Rate | 2015 |
Novel mechanisms and treatment of idiopathic pulmonary fibrosis.
Topics: Clinical Trials as Topic; Disease Progression; Environmental Exposure; Fibroblasts; Gastroesophageal Reflux; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mutation; Myofibroblasts; Polymorphism, Genetic; Prognosis; Pyridones; Treatment Outcome | 2015 |
Update in Interstitial Lung Disease 2014.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Doxycycline; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Lymphangioleiomyomatosis; Pyridones; Sarcoidosis, Pulmonary; Sirolimus; Smoking; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha | 2015 |
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
Topics: Aging; Clinical Trials, Phase II as Topic; Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Pyridones | 2016 |
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2015 |
Therapeutic advances in idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2016 |
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azathioprine; Bayes Theorem; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Etanercept; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Interferon-gamma; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Recombinant Proteins; Sulfonamides; Vital Capacity; Warfarin | 2016 |
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Topics: Acetylcysteine; Adult; Anticoagulants; Bayes Theorem; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Male; Middle Aged; Pyridones; Quality of Life; Treatment Outcome; Young Adult | 2016 |
Therapeutic advances for primary biliary cholangitis: the old and the new.
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cyclosporine; Enzyme Inhibitors; Fibric Acids; Glucocorticoids; Humans; Immunosuppressive Agents; Indoles; Liver Cirrhosis, Biliary; Mesenchymal Stem Cell Transplantation; Methotrexate; Mycophenolic Acid; Pyridones; Rituximab; Tacrolimus; Ursodeoxycholic Acid; Ustekinumab | 2016 |
[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Kidney Diseases; Pyridones; Respiratory System Agents; Treatment Outcome | 2016 |
Pharmacological management of IPF.
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunomodulation; Immunosuppressive Agents; Indoles; Male; Middle Aged; Practice Guidelines as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Recent Advances and Future Needs in Interstitial Lung Diseases.
Topics: Clinical Trials as Topic; Forecasting; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Pyridones; Quality of Life | 2016 |
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Therapeutic Approach to Adult Fibrotic Lung Diseases.
Topics: Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Diseases; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Prognosis; Pyridones | 2016 |
Pulmonary Fibrosis in Hermansky-Pudlak Syndrome.
Topics: Animals; Biomarkers; Disease Progression; Hermanski-Pudlak Syndrome; Hispanic or Latino; Humans; Indoles; Lung Transplantation; Membrane Proteins; Mice; Mutation; Puerto Rico; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed | 2016 |
The safety of new drug treatments for idiopathic pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2016 |
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Precision Medicine; Prognosis; Pyridones | 2017 |
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2017 |
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Topics: Acetylcysteine; Adult; Cost-Benefit Analysis; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Markov Chains; Models, Economic; Pyridones; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom | 2017 |
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antioxidants; Apoptosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; NADPH Oxidase 1; NADPH Oxidase 4; NADPH Oxidases; Patents as Topic; Protein Kinase Inhibitors; Pyridones; Receptors, Lysophosphatidic Acid | 2017 |
The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis.
Topics: Disease Progression; Early Diagnosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Patient Care Team; Patient-Centered Care; Prognosis; Protein Kinase Inhibitors; Pyridones | 2017 |
Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Endpoint Determination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Phosphodiesterase 5 Inhibitors; Pyridones; Survival Rate | 2017 |
Clinical trial research in focus: why do so many clinical trials fail in IPF?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Research Design; Treatment Failure | 2017 |
Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Enzyme Inhibitors; Genotype; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Phenotype; Precision Medicine; Pyridones | 2017 |
Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Fibrinolytic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein-Tyrosine Kinases; Pyridones | 2017 |
Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?).
Topics: Disease Progression; Enzyme Inhibitors; Humans; Indoles; Lung Diseases, Interstitial; Observational Studies as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies?
Topics: Antihypertensive Agents; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endpoint Determination; Epoprostenol; Forecasting; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Indoles; Lung Diseases, Interstitial; Phosphodiesterase 5 Inhibitors; Pilot Projects; Protein-Tyrosine Kinases; Pulmonary Disease, Chronic Obstructive; Pyridones | 2018 |
Model-based Meta-Analysis on the Efficacy of Pharmacological Treatments for Idiopathic Pulmonary Fibrosis.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Models, Statistical; Pyridones; Regression Analysis; Treatment Outcome; Vital Capacity | 2017 |
Current approaches to the management of idiopathic pulmonary fibrosis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Middle Aged; Palliative Care; Patient Education as Topic; Practice Guidelines as Topic; Prevalence; Pyridones; Quality of Life; Young Adult | 2017 |
Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Decision Making; Disease Management; Drug-Related Side Effects and Adverse Reactions; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Vital Capacity | 2017 |
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Approval; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Therapeutic targets in idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Pyridones; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2017 |
Severe idiopathic pulmonary fibrosis: what can be done?
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Palliative Care; Pyridones; Respiratory Function Tests; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.
Topics: Animals; Diffusion of Innovation; Disease Progression; Drug Discovery; Drugs, Investigational; Forecasting; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Remission Induction; Respiratory System Agents; Severity of Illness Index; Treatment Outcome | 2017 |
Nintedanib for Idiopathic Pulmonary Fibrosis.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones | 2019 |
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2017 |
Idiopathic pulmonary fibrosis: pathogenesis and management.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Tomography, X-Ray Computed | 2018 |
[Nintedanib in the treatment of fibrosing interstital lung diseases].
Topics: Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridones; Treatment Outcome | 2018 |
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Design; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2018 |
Idiopathic Pulmonary Fibrosis.
Topics: Diagnosis, Differential; Dyspnea; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Oxygen Inhalation Therapy; Prognosis; Pyridones; Risk Factors; Tomography, X-Ray Computed; Transforming Growth Factor beta | 2018 |
Japanese guideline for the treatment of idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Glycine; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Japan; Lung Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic; Prognosis; Pyridones; Quality of Health Care; Sulfonamides; Survival Rate | 2018 |
Use of animal models in IPF research.
Topics: Animals; Bleomycin; Disease Models, Animal; Drug Development; Drug Evaluation, Preclinical; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Respiratory Function Tests | 2018 |
Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2018 |
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
Topics: Disease Progression; Humans; Indoles; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Treatment Outcome | 2018 |
Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis.
Topics: Aged; Biopsy, Needle; Chronic Disease; Comprehension; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunohistochemistry; Indoles; Lung Transplantation; Male; Middle Aged; Precision Medicine; Prognosis; Pyridones; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Myofibroblasts; Pyridones | 2019 |
Inflammation and immunity in IPF pathogenesis and treatment.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Clinical Trials as Topic; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Immunity, Innate; Indoles; Inflammation; Protein Kinase Inhibitors; Pyridones | 2019 |
Fibrosing interstitial lung diseases: knowns and unknowns.
Topics: Disease Progression; Health Status; Humans; Indoles; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Quality of Life; Respiratory System Agents; Risk Factors; Severity of Illness Index; Treatment Outcome | 2019 |
Evaluation and management of Idiopathic Pulmonary Fibrosis.
Topics: Biomarkers; Chronic Disease; Cough; Diagnosis, Differential; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; L-Lactate Dehydrogenase; Mucin-1; Pyridones; Respiratory Function Tests; Tomography, X-Ray Computed; Vital Capacity | 2019 |
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options.
Topics: Aging; Drug Development; Extracellular Matrix; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2019 |
Current and Future Idiopathic Pulmonary Fibrosis Therapy.
Topics: Anti-Inflammatory Agents; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2019 |
Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.
Topics: Age Distribution; Aging; Antineoplastic Agents; Chronic Disease; Comorbidity; Disease Progression; Health Expenditures; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Sex Distribution | 2019 |
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Indoles; Kaplan-Meier Estimate; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Tomography, X-Ray Computed | 2019 |
The therapy of idiopathic pulmonary fibrosis: what is next?
Topics: Animals; Comorbidity; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Molecular Targeted Therapy; Palliative Care; Pyridones; Respiratory System Agents; Respiratory Therapy; Risk Factors; Treatment Outcome | 2019 |
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones; Time-to-Treatment | 2019 |
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones; Treatment Outcome | 2019 |
Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
Topics: Antibodies, Monoclonal, Humanized; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Pyridones; Randomized Controlled Trials as Topic; Rituximab; Scleroderma, Systemic; Transplantation, Autologous | 2019 |
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
Topics: Animals; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Diseases, Interstitial; Pyridones; Treatment Outcome; Vital Capacity | 2019 |
[Progress in randomized clinical trials of antifibrotic drug nintedanib and pirfenidone].
Topics: Fibrosis; Humans; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2020 |
Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions.
Topics: Behavior; Cardiovascular Diseases; Comorbidity; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Muscle Strength; Nutrition Assessment; Nutrition Disorders; Nutritional Physiological Phenomena; Nutritional Status; Patient Education as Topic; Pyridones | 2020 |
Evolution and treatment of idiopathic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Connective Tissue Growth Factor; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Integrins; Leukotriene Antagonists; Lung Transplantation; Microbiota; Middle Aged; Multimorbidity; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Kinase Inhibitors; Pyridones; Serum Amyloid P-Component | 2020 |
Lung transplantation for idiopathic pulmonary fibrosis.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Comorbidity; Disease Progression; Frailty; Gastroesophageal Reflux; Humans; Hypertension, Pulmonary; Idiopathic Interstitial Pneumonias; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Lung Transplantation; Prognosis; Pyridones; Telomere Shortening | 2020 |
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Connective Tissue Growth Factor; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2020 |
Shedding light on developmental drugs for idiopathic pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Development; Drug Discovery; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones | 2020 |
[Antifibrotic therapy and progressive lung fibrosis].
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pulmonary Fibrosis; Pyridones | 2020 |
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Vital Capacity | 2020 |
Autophagy and Pulmonary Fibrosis.
Topics: Autophagy; Disease Progression; Humans; Indoles; Pulmonary Fibrosis; Pyridones | 2020 |
Advances in lung transplantation for interstitial lung diseases.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Extracorporeal Membrane Oxygenation; Humans; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Nutritional Status; Patient Selection; Perioperative Care; Preoperative Care; Protein Kinase Inhibitors; Pyridones | 2020 |
Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cough; Dyspnea; Fatigue; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mental Health; Protein Kinase Inhibitors; Pyridones; Quality of Life | 2020 |
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options.
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2021 |
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2021 |
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.
Topics: Anti-Inflammatory Agents, Non-Steroidal; COVID-19; Humans; Indoles; Lung; Patient Discharge; Pulmonary Fibrosis; Pyridones; Severity of Illness Index; Signal Transduction | 2021 |
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient Education as Topic; Protein Kinase Inhibitors; Pyridones; Randomized Controlled Trials as Topic | 2021 |
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials.
Topics: Animals; Clinical Trials, Phase II as Topic; Drug Design; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Pyridones; Randomized Controlled Trials as Topic | 2021 |
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Topics: Antifibrotic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Mortality; Pyridones; Symptom Flare Up; Treatment Outcome | 2021 |
COVID-related fibrosis: insights into potential drug targets.
Topics: Animals; Antifibrotic Agents; COVID-19; Critical Illness; Humans; Indoles; Pulmonary Fibrosis; Pyridones | 2021 |
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrotic Agents; Cause of Death; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Fibrosis; Pyridones; Treatment Outcome | 2021 |
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Pyridones; Treatment Outcome | 2023 |
9 trial(s) available for pirfenidone and nintedanib
| Article | Year |
|---|---|
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Male; Middle Aged; Patient Safety; Pyridones; Treatment Outcome; Vital Capacity | 2015 |
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
Topics: Aged; Aged, 80 and over; Amino Acid Oxidoreductases; Antibodies, Monoclonal, Humanized; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Treatment Outcome | 2017 |
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Topics: Aged; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Patient Safety; Pyridones; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2018 |
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Internationality; Lung; Male; Middle Aged; Pyridones; Treatment Outcome; Vital Capacity | 2018 |
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
Topics: Acetates; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Patient Safety; Pyridones; Treatment Outcome | 2019 |
Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Anxiety; Depression; Disease Management; Female; Home Care Services; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Netherlands; Patient Reported Outcome Measures; Pyridones; Quality of Life; Spirometry; Telemedicine; Vital Capacity | 2020 |
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Motivation; Patient Satisfaction; Prospective Studies; Pyridones; Self Report; Surveys and Questionnaires; Treatment Outcome | 2020 |
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Propensity Score; Pyridones; Sildenafil Citrate; Treatment Outcome; Vital Capacity | 2021 |
Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration.
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome; Vital Capacity | 2022 |
132 other study(ies) available for pirfenidone and nintedanib
| Article | Year |
|---|---|
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.
Topics: Animals; Carboxylic Acids; Connective Tissue Growth Factor; Enzyme Inhibitors; Female; Fibrosis; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Oxadiazoles; rho GTP-Binding Proteins; Scleroderma, Systemic; Serum Response Factor; Signal Transduction; Skin; Structure-Activity Relationship; Trans-Activators; Transcription, Genetic | 2019 |
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Idiopathic Pulmonary Fibrosis; Janus Kinase 3; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2020 |
Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases.
Topics: Acetylcysteine; Biopsy; Bronchoalveolar Lavage Fluid; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Contraindications; Diagnostic Imaging; Disease Progression; Evidence-Based Medicine; Gastroesophageal Reflux; Genetic Therapy; Glucocorticoids; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Incidence; Indoles; Lung; Lung Transplantation; Oxygen Inhalation Therapy; Palliative Care; Prevalence; Prognosis; Pulmonary Emphysema; Pyridones; Risk Factors; Spain | 2013 |
A new hope for idiopathic pulmonary fibrosis.
Topics: Antifibrinolytic Agents; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Protein Kinase Inhibitors; Pyridones | 2014 |
InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Industry; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Hot off the breath: A big step forward for idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2014 |
2014 American Thoracic Society International Conference.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Asthma; Congresses as Topic; Eosinophilia; Expectorants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridones; Respiratory Distress Syndrome | 2014 |
[Idiopathic pulmonary fibrosis: A new era, new challenges].
Topics: Acetylcysteine; Clinical Trials as Topic; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2014 |
Landmark approvals in idiopathic pulmonary fibrosis.
Topics: Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; United States; United States Food and Drug Administration | 2014 |
A new era of drug therapy for idiopathic pulmonary fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Middle Aged; Pyridones; Randomized Controlled Trials as Topic | 2014 |
Novel treatments for idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein-Tyrosine Kinases; Pyridones | 2015 |
Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2015 |
Update in diffuse parenchymal lung disease, 2013.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Drug Approval; Enzyme Inhibitors; Genomics; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Polymorphism, Genetic; Pyridones; Treatment Outcome; United States; United States Food and Drug Administration | 2015 |
[Two drugs inhibit disease progression. Idiopathic lung fibrosis treatable for the first time].
Topics: Acetylcysteine; Disease Progression; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Vital Capacity | 2015 |
Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Drug Approval; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; United States; United States Food and Drug Administration; Vital Capacity | 2015 |
[Systemic sclerosis - an update].
Topics: Algorithms; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Endothelin Receptor Antagonists; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Indoles; Pulmonary Artery; Pyrazoles; Pyridones; Pyrimidines; Rituximab; Scleroderma, Systemic; Sulfonamides | 2015 |
Two therapies now available for idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Vital Capacity | 2014 |
[Two new drugs for the treatment of idiopathic lung fibrosis: A new therapeutic era!].
Topics: Antineoplastic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2015 |
Developments in the management of idiopathic pulmonary fibrosis.
Topics: Disease Progression; Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Orphan Drug Production; Pyridones; United Kingdom | 2015 |
[Pulmonary fibrosis].
Topics: Acetylcysteine; Azathioprine; Clinical Trials as Topic; Forecasting; Glucocorticoids; Humans; Indoles; Multicenter Studies as Topic; Prognosis; Pulmonary Fibrosis; Pyridones | 2016 |
Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough.
Topics: Clinical Trials, Phase III as Topic; Data Collection; Data Interpretation, Statistical; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Randomized Controlled Trials as Topic; Respiratory Function Tests; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Survival Rate; Treatment Outcome; Vital Capacity | 2015 |
Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Body Mass Index; Compassionate Use Trials; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Respiratory Function Tests; Retrospective Studies; Vital Capacity | 2015 |
New guideline on treatment of idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones | 2015 |
[Idiopathic Pulmonary Fibrosis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Respiratory System Agents; Treatment Outcome | 2015 |
Therapeutic advances in idiopathic pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2016 |
Pulmonary Fibrosis Foundation Summit 2015.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Clinical Trials as Topic; Congresses as Topic; Drug Approval; Enzyme Inhibitors; Humans; Indoles; Patient Selection; Pulmonary Fibrosis; Pyridones; Rare Diseases | 2016 |
"The Long and Winding Road" seeking specific drugs for idiopathic pulmonary fibrosis.
Topics: Clinical Trials as Topic; Drug Discovery; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Pyridones; United States | 2016 |
Idiopathic pulmonary fibrosis: the role of the pharmacy benefit manager in providing access to effective, high-value care.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Management; Drug Costs; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Insurance, Pharmaceutical Services; Pharmacies; Pyridones; United States | 2015 |
Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Myofibroblasts; Pyridones; Treatment Outcome | 2016 |
Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Pyridones; Tomography, X-Ray Computed; Vital Capacity | 2016 |
Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Vital Capacity | 2016 |
Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Biopsy; Comorbidity; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Indoles; Male; Pyridones; Tomography, X-Ray Computed | 2016 |
MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis.
Topics: A549 Cells; Animals; Bleomycin; Bronchoalveolar Lavage; Cell Line, Tumor; Disease Models, Animal; Epithelial Cells; Female; HeLa Cells; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Injury; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta; Up-Regulation | 2016 |
Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis.
Topics: Aged; Aged, 80 and over; Belgium; Biomarkers; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Male; Middle Aged; Mucin-1; Prospective Studies; Pyridones | 2016 |
COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Decision Making; Drug Tolerance; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2016 |
POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Decision Making; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2016 |
Respiratory Conditions Update: Restrictive Lung Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Continuous Positive Airway Pressure; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Obesity Hypoventilation Syndrome; Oxygen Inhalation Therapy; Polysomnography; Pyridones; Respiratory Function Tests; Respiratory Therapy; Sleep Apnea, Obstructive; Weight Loss | 2016 |
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Disease Progression; Female; Graft Survival; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Male; Middle Aged; Postoperative Complications; Pyridones; Retrospective Studies; Tertiary Care Centers; Vital Capacity | 2016 |
3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Case-Control Studies; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Models, Biological; Myofibroblasts; Precision Medicine; Pyridones; Spheroids, Cellular; Transforming Growth Factor beta1 | 2017 |
A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Topics: Collagen Type I; Down-Regulation; Extracellular Matrix Proteins; Fibrillar Collagens; Fibroblasts; HSP47 Heat-Shock Proteins; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Protein Processing, Post-Translational; Pyridones; Tacrolimus Binding Proteins; Transcription, Genetic | 2017 |
Improving Survival in Idiopathic Pulmonary Fibrosis: The Race Has Just Begun.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Survival Analysis; Tumor Necrosis Factor-alpha | 2017 |
Guidelines for the medical treatment of idiopathic pulmonary fibrosis.
Topics: Adrenal Cortex Hormones; Disease Progression; Disease-Free Survival; Evidence-Based Medicine; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Meta-Analysis as Topic; Pulmonary Emphysema; Pyridones; Randomized Controlled Trials as Topic; Societies, Medical; Spain | 2017 |
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome | 2017 |
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Multivariate Analysis; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vital Capacity | 2017 |
Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Fibrosis; Pyridones | 2017 |
Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Early Diagnosis; Early Medical Intervention; Enzyme Inhibitors; Health Behavior; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Patient-Centered Care; Precision Medicine; Prognosis; Pyridones; Tomography, X-Ray Computed | 2017 |
New treatment directions for IPF: current status of ongoing and upcoming clinical trials.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2017 |
Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management.
Topics: Acute Disease; Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Bronchoalveolar Lavage Fluid; Chronic Disease; Disease Progression; Enzyme Inhibitors; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung; Lung Transplantation; Pyridones; Tomography, X-Ray Computed | 2017 |
Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary Fibrosis.
Topics: Animals; Collagen; Humans; Indoles; Pulmonary Fibrosis; Pyridones | 2017 |
Idiopathic Pulmonary Fibrosis: A Case Discussion.
Topics: Aged; Drug Interactions; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pharmacists; Professional Role; Pyridones | 2017 |
Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Comorbidity; Disease Progression; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; New Zealand; Pulmonary Medicine; Pyridones; Randomized Controlled Trials as Topic; Societies, Medical | 2017 |
Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Europe; Female; Health Services Needs and Demand; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Severity of Illness Index; Surveys and Questionnaires; Vital Capacity | 2017 |
Evaluating new treatment options.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung; Male; Middle Aged; Pyridones; United States | 2017 |
Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis?
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2018 |
Recommendations for perioperative management of new pharmacological antifibrotic therapy in idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Fibroblasts; Hemodynamics; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Intraoperative Complications; Multicenter Studies as Topic; Perioperative Care; Postoperative Complications; Preanesthetic Medication; Pyridones; Vital Capacity | 2018 |
Pirfenidone-induced hyponatraemia: insight in mechanism, risk factor and management.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Female; Humans; Hyponatremia; Idiopathic Pulmonary Fibrosis; Inappropriate ADH Syndrome; Indoles; Male; Pyridones; Retrospective Studies; Risk Factors | 2017 |
Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy.
Topics: Evidence-Based Medicine; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Lung Diseases, Interstitial; Phenotype; Pyridones; Risk Assessment; Scleroderma, Systemic | 2018 |
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.
Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Antacids; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Female; Gastroesophageal Reflux; Guideline Adherence; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2018 |
Health economic evaluation in idiopathic pulmonary fibrosis in France.
Topics: Cost-Benefit Analysis; Disease Progression; Female; France; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Quality of Life; Quality-Adjusted Life Years; Respiratory System Agents; Treatment Outcome | 2018 |
Idiopathic pulmonary fibrosis: A guide for nurse practitioners.
Topics: Clinical Trials as Topic; Disease Management; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Nurse Practitioners; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Respiratory System Agents; Self-Management; Tomography, X-Ray Computed | 2018 |
Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Topics: Actins; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Culture Media, Conditioned; Drug Combinations; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Laminin; Phenotype; Phosphorylation; Primary Cell Culture; Proteoglycans; Pyridones; Signal Transduction; Smad3 Protein; STAT3 Transcription Factor; Transforming Growth Factor beta | 2018 |
Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis.
Topics: Europe; Female; Humans; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Male; Middle Aged; Postoperative Care; Pyridones; Retrospective Studies; Steroids; Treatment Outcome | 2018 |
Fibrotic microtissue array to predict anti-fibrosis drug efficacy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Drug Evaluation, Preclinical; Fibroblasts; Fibrosis; Humans; Indoles; Lung; Lung Compliance; Primary Cell Culture; Pulmonary Fibrosis; Pyridones; Tissue Culture Techniques; Tissue Scaffolds; Treatment Outcome | 2018 |
A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts.
Topics: Cell Line; Down-Regulation; Extracellular Matrix; Fibroblasts; Guanine Nucleotide Exchange Factors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Phenotype; Pyridones; Repressor Proteins; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Transforming Growth Factor beta; Up-Regulation | 2018 |
Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2018 |
Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2018 |
Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Topics: Aged; Alveolar Epithelial Cells; Cell Line, Tumor; Female; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Pyridones | 2019 |
[The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Design; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones | 2016 |
Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Topics: Alveolar Epithelial Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cell Culture Techniques; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mice; Mice, Inbred C57BL; Pyridones | 2018 |
New era of Idiopathic Pulmonary Fibrosis.
Topics: Biomarkers; Cell- and Tissue-Based Therapy; Female; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Mesenchymal Stem Cells; Pyridones; Respiratory Function Tests | 2018 |
Molecular characterization of a precision-cut rat lung slice model for the evaluation of antifibrotic drugs.
Topics: Animals; Biomarkers; Collagen Type I; Extracellular Matrix; Fibrosis; Indoles; Lung; Pyridones | 2019 |
Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Topics: Aged; Animals; Antineoplastic Agents; Female; Fibrosis; Fluorodeoxyglucose F18; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Mice; Mice, Inbred C57BL; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Pyridones | 2019 |
Case 10-2019: A 69-Year-Old Man with Progressive Dyspnea.
Topics: Aged; Alveolitis, Extrinsic Allergic; Biopsy; Diagnosis, Differential; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Pyridones; Radiography, Thoracic; Sarcoidosis; Tomography, X-Ray Computed | 2019 |
Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Anorexia; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Logistic Models; Lung; Male; Middle Aged; Multivariate Analysis; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity; Weight Loss | 2019 |
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Approval; Drug Development; Drug Interactions; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient Outcome Assessment; Protein Kinase Inhibitors; Pyridones; Quality of Life; Standard of Care; Vital Capacity; Walk Test | 2019 |
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Mortality; Propensity Score; Protein Kinase Inhibitors; Pyridones; Treatment Outcome; United States; Young Adult | 2019 |
Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Medicine, Chinese Traditional; Meta-Analysis as Topic; Network Meta-Analysis; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Respiratory Function Tests; Severity of Illness Index; Survival Analysis; Systematic Reviews as Topic | 2019 |
The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models.
Topics: Animals; Biguanides; Bleomycin; Disease Models, Animal; Epithelial-Mesenchymal Transition; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mice; Pyridones; Republic of Korea | 2019 |
Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis.
Topics: Bias; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Research Design; Treatment Outcome | 2019 |
Improving outcomes and managing costs in idiopathic pulmonary fibrosis.
Topics: Antineoplastic Agents; Chronic Disease; Comorbidity; Cost of Illness; Health Expenditures; Health Resources; Health Services; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Medication Adherence; Patient Care Management; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Quality of Life; Registries | 2019 |
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Gastrointestinal Diseases; Health Care Surveys; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Netherlands; Pyridones; Risk Assessment; Risk Factors; Self Report; Time Factors; Treatment Outcome | 2019 |
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dust; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Male; Middle Aged; Multivariate Analysis; Occupational Exposure; Prognosis; Prospective Studies; Pyridones; Regression Analysis; Respiratory Function Tests; Treatment Outcome | 2019 |
Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyridones; Severity of Illness Index; Weight Loss | 2019 |
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
Topics: Carbon Monoxide; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Time Factors; Vital Capacity | 2019 |
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Topics: Aged; Disease Progression; Female; Humans; Indoles; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Phenotype; Pulmonary Fibrosis; Pyridones; Retrospective Studies; Risk Factors; Tertiary Care Centers; Tomography, X-Ray Computed | 2019 |
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Biomarkers; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Logistic Models; Male; Middle Aged; Mucin-1; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity | 2020 |
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Foundations; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Patient Participation; Protein Kinase Inhibitors; Pyridones; Registries; United States | 2020 |
[Progress in randomized clinical trials of antifibrotic drug nintedanib and pirfenidone].
Topics: Humans; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2020 |
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study.
Topics: Antineoplastic Agents; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Longitudinal Studies; Male; Middle Aged; Mortality; Practice Patterns, Physicians'; Pyridones; Treatment Outcome | 2020 |
The world is not enough - the value of increasing registry data in idiopathic pulmonary fibrosis.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Registries; United States | 2020 |
Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cells, Cultured; Cicatrix; Collagen; Drug Evaluation, Preclinical; Extracellular Matrix; Fibroblasts; Fibronectins; Fibrosis; Humans; Indoles; Protein Kinase Inhibitors; Pyridones; Transforming Growth Factor beta1 | 2020 |
Idiopathic pulmonary fibrosis: Significance of the usual interstitial pneumonia (UIP) CT-scan patterns defined in new international guidelines.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diagnostic Techniques, Respiratory System; Female; France; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Internationality; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyridones; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Survival Rate | 2020 |
Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Comparative Effectiveness Research; Female; Health Care Costs; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Logistic Models; Male; Medicare; Medication Adherence; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; United States | 2020 |
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Indoles; Lung Diseases, Interstitial; Phenotype; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity | 2020 |
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cell Proliferation; Cell Survival; Chemokine CCL2; Coculture Techniques; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Mast Cells; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridones; Rats; Recombinant Proteins; Signal Transduction; Stem Cell Factor; Vital Capacity | 2020 |
Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
Topics: Aged; Aged, 80 and over; Comparative Effectiveness Research; Delivery of Health Care; Female; Health Care Costs; Health Services; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Medicare; Patient Acceptance of Health Care; Pyridones; Retrospective Studies; Treatment Outcome; United States | 2020 |
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Longitudinal Studies; Lung; Male; Middle Aged; Models, Biological; Prognosis; Pyridones; Respiratory Function Tests; Risk Factors; Smoking; Time Factors; Treatment Outcome; Vital Capacity | 2021 |
Lung Myofibroblasts Promote Macrophage Profibrotic Activity through Lactate-induced Histone Lactylation.
Topics: Animals; Cells, Cultured; Histones; Humans; Indoles; Lactates; Lung; Macrophages, Alveolar; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Pulmonary Fibrosis; Pyridones | 2021 |
Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis.
Topics: Animals; Apoptosis; Bleomycin; Capillaries; Dicarboxylic Acids; Endothelial Cells; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Mice; Mice, Inbred C57BL; Pyridones; Regeneration | 2020 |
Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention.
Topics: Acetylcysteine; Convalescence; COVID-19; COVID-19 Drug Treatment; Early Medical Intervention; Glucocorticoids; Humans; Indoles; Pulmonary Fibrosis; Pyridones; SARS-CoV-2 | 2021 |
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Mutation; Pyridones; Telomere; Treatment Outcome | 2021 |
Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton's jelly.
Topics: Animals; Bleomycin; Humans; Indoles; Lung; Mesenchymal Stem Cells; Pulmonary Fibrosis; Pyridones; Rats; Wharton Jelly | 2020 |
Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury.
Topics: Animals; Drug Repositioning; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; MicroRNAs; Myocardial Reperfusion Injury; Protein Kinase Inhibitors; Pyridones; Signal Transduction; src-Family Kinases; ST Elevation Myocardial Infarction | 2021 |
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis.
Topics: Aged; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Medicare; Pharmaceutical Preparations; Pyridones; Retrospective Studies; Treatment Outcome; United States | 2021 |
[Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Indoles; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Pyridones; Randomized Controlled Trials as Topic | 2021 |
Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones | 2021 |
Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis.
Topics: Antigens; B-Lymphocytes; Cell Aggregation; Cell Movement; Cell Proliferation; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Inflammation Mediators; Interleukin-6; Pneumonia; Pyridones; src-Family Kinases; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2021 |
Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Retrospective Studies; Treatment Outcome | 2022 |
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
Topics: Aged; Aged, 80 and over; Databases, Factual; Disease Progression; Female; France; Health Status; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Respiratory System Agents; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Use of Nintedanib and Pirfenidone in Non-Idiopathic Pulmonary Fibrosis Lung Disease.
Topics: Humans; Indoles; Lung Diseases; Pyridones | 2021 |
Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Pyridones; Retrospective Studies; Treatment Outcome | 2021 |
Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs.
Topics: Cells, Cultured; Drug Evaluation, Preclinical; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lab-On-A-Chip Devices; Models, Biological; Pyridones | 2021 |
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
Topics: Biological Factors; COVID-19; COVID-19 Drug Treatment; Humans; Indoles; Lung; Mesenchymal Stem Cells; Pulmonary Fibrosis; Pyridones; SARS-CoV-2 | 2021 |
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Male; Middle Aged; Pyridones; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Vital Capacity; Walk Test | 2021 |
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
Topics: Aged; Disease Progression; Drug Administration Schedule; Drug Substitution; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Male; Prognosis; Propensity Score; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity | 2021 |
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cohort Studies; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Logistic Models; Male; Middle Aged; Mortality; Propensity Score; Protein Kinase Inhibitors; Pyridones; Treatment Outcome; United States | 2021 |
Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome; Vital Capacity | 2021 |
Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
Topics: Aged; Aged, 80 and over; Antifibrotic Agents; Disease Progression; Female; Humans; Incidence; Indoles; Male; Pulmonary Fibrosis; Pyridones; Time Factors; Treatment Outcome | 2021 |
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antifibrotic Agents; Drug Costs; Female; Hospital Costs; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia.
Topics: Australia; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2021 |
Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Topics: Aged; Aged, 80 and over; Antifibrotic Agents; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Prospective Studies; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity | 2021 |
Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
Topics: Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2022 |
Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
Topics: Aged; Antifibrotic Agents; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Transplantation; Male; Perioperative Period; Pyridones; Retrospective Studies; Vital Capacity; Waiting Lists; Weight Loss | 2021 |
Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrotic Agents; Cost of Illness; Cost-Benefit Analysis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Markov Chains; Protein Kinase Inhibitors; Pyridones; United States | 2022 |
Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Topics: Antineoplastic Agents; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Prognosis; Pyridones; Treatment Outcome | 2022 |
Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones | 2023 |
Integrated bioinformatics analysis identifies established and novel TGFβ1-regulated genes modulated by anti-fibrotic drugs.
Topics: Adaptor Proteins, Vesicular Transport; Antifibrotic Agents; Cadherins; Cell Adhesion Molecule-1; Computational Biology; Extracellular Matrix Proteins; Female; Gene Expression Regulation; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Interleukins; Male; Membrane Proteins; Nerve Tissue Proteins; Pyridones; Racemases and Epimerases; Repressor Proteins; Tensins; Transforming Growth Factor beta | 2022 |
Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome | 2022 |
Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study.
Topics: Adult; C-Reactive Protein; COVID-19 Drug Treatment; Ferritins; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Middle Aged; Prednisolone; Pyridones; Treatment Outcome | 2022 |
Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
Topics: Delivery of Health Care; Humans; Idiopathic Pulmonary Fibrosis; Indoles | 2023 |
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Topics: Administration, Oral; Aged; Clinical Trials, Phase III as Topic; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Multicenter Studies as Topic; Phosphodiesterase Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Respiratory Physiological Phenomena; Respiratory System Agents; Treatment Outcome | 2023 |